{
    "2021-07-15": [
        [
            {
                "time": "",
                "original_text": "贝达药业PD-1+CTLA-4联合治疗实体瘤临床试验获批",
                "features": {
                    "keywords": [
                        "PD-1",
                        "CTLA-4",
                        "联合治疗",
                        "实体瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：目前，公司也在积极推进向美国食品药品监督管理局提交恩沙替尼一线适应症的上市申请准备工作。CM082肾癌适应症的新药注册申报准备工作正在有序推进中",
                "features": {
                    "keywords": [
                        "恩沙替尼",
                        "CM082",
                        "肾癌",
                        "FDA",
                        "上市申请"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：PD-1抗体和CTLA-4抗体联用治疗晚期实体瘤获批临床试验",
                "features": {
                    "keywords": [
                        "PD-1抗体",
                        "CTLA-4抗体",
                        "晚期实体瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：两项药品临床试验已获批开展",
                "features": {
                    "keywords": [
                        "药品",
                        "临床试验",
                        "获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：两项联用治疗晚期实体瘤药品获临床试验批准通知书",
                "features": {
                    "keywords": [
                        "联用治疗",
                        "晚期实体瘤",
                        "临床试验",
                        "批准通知书"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：公司两项药品获临床试验批准",
                "features": {
                    "keywords": [
                        "药品",
                        "临床试验",
                        "批准"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：目前公司未持有北京加科思新药研发有限公司股份",
                "features": {
                    "keywords": [
                        "北京加科思",
                        "新药研发",
                        "股份"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：公司目前持有北京华昊中天生物医药股份有限公司3.17658%的股权",
                "features": {
                    "keywords": [
                        "北京华昊中天",
                        "生物医药",
                        "股权"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业CTLA-4单抗用于晚期实体瘤获批临床",
                "features": {
                    "keywords": [
                        "CTLA-4单抗",
                        "晚期实体瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}